R.H. Bluestein & Co’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$578K Sell
7,600
-500
-6% -$41.4K 0.04% 131
2022
Q2
$685K Sell
8,100
-2,000
-20% -$175K 0.04% 134
2022
Q1
$886K Hold
10,100
0.04% 118
2021
Q4
$883K Hold
10,100
0.03% 119
2021
Q3
$826K Hold
10,100
0.03% 138
2021
Q2
$922K Hold
10,100
0.04% 134
2021
Q1
$863K Hold
10,100
0.04% 121
2020
Q4
$954K Hold
10,100
0.04% 105
2020
Q3
$878K Hold
10,100
0.04% 104
2020
Q2
$882K Sell
10,100
-100
-1% -$8.63K 0.05% 99
2020
Q1
$841K Buy
10,200
+40
+0.4% +$3.57K 0.07% 84
2019
Q4
$962K Sell
10,160
-160
-2% -$14.4K 0.05% 82
2019
Q3
$897K Hold
10,320
0.05% 77
2019
Q2
$942K Sell
10,320
-952
-8% -$80.6K 0.05% 73
2019
Q1
$971K Hold
11,272
0.05% 72
2018
Q4
$867K Sell
11,272
-2,343
-17% -$182K 0.07% 58
2018
Q3
$1.05M Hold
13,615
0.05% 79
2018
Q2
$922K Sell
13,615
-1,563
-10% -$108K 0.05% 82
2018
Q1
$1.1M Sell
15,178
-1,680
-10% -$128K 0.06% 83
2017
Q4
$1.27M Buy
16,858
+6
+0% +$453 0.07% 65
2017
Q3
$1.3M Sell
16,852
-558
-3% -$42.1K 0.07% 68
2017
Q2
$1.3M Hold
17,410
0.08% 65
2017
Q1
$1.16M Buy
17,410
+558
+3% +$37.2K 0.07% 67
2016
Q4
$1.1M Sell
16,852
-17
-0.1% -$1.1K 0.07% 64
2016
Q3
$1.19M Buy
16,869
+17
+0.1% +$1.24K 0.08% 55
2016
Q2
$1.25M Sell
16,852
-111
-0.7% -$7.67K 0.1% 46
2016
Q1
$1.1M Hold
16,963
0.08% 65
2015
Q4
$1.31M Hold
16,963
0.08% 64
2015
Q3
$1.4M Sell
16,963
-112
-0.7% -$9.97K 0.1% 60
2015
Q2
$1.5M Hold
17,075
0.09% 66
2015
Q1
$1.51M Sell
17,075
-120
-0.7% -$10.6K 0.09% 72
2014
Q4
$1.43M Hold
17,195
0.09% 79
2014
Q3
$1.45M Sell
17,195
-213
-1% -$17.2K 0.09% 81
2014
Q2
$1.41M Buy
17,408
+361
+2% +$28.4K 0.08% 81
2014
Q1
$1.3M Hold
17,047
0.09% 90
2013
Q4
$1.23M Sell
17,047
-5,385
-24% -$374K 0.08% 91
2013
Q3
$1.54M Hold
22,432
0.11% 77
2013
Q2
$1.42M Buy
+22,432
New +$1.46M 0.12% 71

Other funds holding NVS

R.H. Bluestein & Co's NVS Position: Q3 2022 in Review

R.H. Bluestein & Co reduced its Novartis (NVS) stake by 6.2% in Q3 2022, selling an estimated $41.4K and leaving 7,600 shares worth $578K. The position accounts for 0.04% of the portfolio, ranked #131.

R.H. Bluestein & Co first reported a position in NVS in Q2 2013 and has held it in 38 quarters since. The position peaked at $1.54M in Q3 2013. 1,088 funds tracked by Wall St. Rank hold NVS as of Q3 2022.

  • R.H. Bluestein & Co held 7,600 shares of Novartis worth $578K as of Q3 2022.
  • R.H. Bluestein & Co sold 500 Novartis shares in Q3 2022, an estimated $41.4K.
  • Novartis made up 0.04% of R.H. Bluestein & Co's portfolio in Q3 2022, its #131 holding.
  • R.H. Bluestein & Co first reported a position in Novartis in Q2 2013 and has held it in 38 quarters since.
  • R.H. Bluestein & Co's Novartis position peaked at $1.54M in Q3 2013.
  • 1,088 funds tracked by Wall St. Rank held Novartis as of Q3 2022.

Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.